Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 6/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7931094 | 0.86 | LMNA (0.46) | LMNATSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL5000772 | 0.86 | LMNA (0.41) | LMNATSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL4752822 | 0.85 | LMNA (0.43) | LMNATSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL7934462 | 0.74 | KMT2A (0.45) | LMNATSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL13076801 | 0.74 | LMNA (0.46) | LMNATSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL13039203 | 0.73 | HTR6 (0.46) | LMNATSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL4101227 | 0.73 | ALDH1A1 (0.46) | LMNATSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL8218043 | 0.73 | HTR6 (0.43) | TSHRALDH1A1KMT2AMEN1PKM | |
| SCHEMBL4752501 | 0.72 | AKR1B1 (0.47) | SMN1; SMN2MAPTKMT2AMEN1PKM | |
| SCHEMBL8193103 | 0.72 | TP53 (0.44) | LMNASMN1; SMN2MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008154347-A1 | SPIROBENZOAZEPINES AS VASOPRESSIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154347-A1 | SPIROBENZOAZEPINES AS VASOPRESSIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306044-A1 | SPIROBENZOAZEPANES AS VASOPRESSIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306044-A1 | SPIROBENZOAZEPANES AS VASOPRESSIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306044-A1 | SPIROBENZOAZEPANES AS VASOPRESSIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306044-A1 | SPIROBENZOAZEPANES AS VASOPRESSIN ANTAGONISTS | AVPR2, AVPR1B, AVPR1A | LMNA 1330/4885TSHR 211/4885SMN1; SMN2 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.